Avalo Therapeutics (AVTX) Net Cash Flow (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Net Cash Flow data on file, last reported at $9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 197.32% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at -$100.0 million (down 769.78% YoY), and the FY2025 full-year result was -$118.6 million, down 193.3% from the prior year.
• Net Cash Flow for Q1 2026 stood at $9.2 million, up from -$11.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $102.8 million in Q1 2024 and bottomed at -$82.7 million in Q2 2025.
• The 5-year median for Net Cash Flow is -$9.5 million (2025), against an average of -$1.7 million.
• The widest annual swing landed in 2022, when Net Cash Flow tumbled 1444.51%; it then surged 2784.25% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$3.9 million in 2022, then grew by 28.33% to -$2.8 million in 2023, then soared by 2004.7% to $52.7 million in 2024, then tumbled by 121.27% to -$11.2 million in 2025, then jumped by 182.18% to $9.2 million in 2026.
• The last three Net Cash Flow figures came in at $9.2 million (Q1 2026), -$11.2 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.

Peer Comparison